<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56890">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01742533</url>
  </required_header>
  <id_info>
    <org_study_id>BKCR-POF-1(Ⅰ)</org_study_id>
    <nct_id>NCT01742533</nct_id>
  </id_info>
  <brief_title>Stem Cell Therapy Combined Hormone Replacement Therapy in Patients With Premature Ovarian Failure</brief_title>
  <official_title>A Phase Ι/Π Study of Human Cord Blood Mononuclear Cells and Human Umbilical Cord Mesenchymal Stem Cells Transplantation Combined With Hormone Replacement Therapy in Patients With Premature Ovarian Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Beike Bio-Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen Beike Bio-Technology Co., Ltd.</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Premature ovarian failure (POF) refers the occurrence of amenorrhoea, elevated serum
      gonadotrophins and hypoestrogenism levels in female before the age of 40. It has important
      physical and psychological consequences/impact in those patients.

      Premature ovarian failure (POF) is currently managed by non-physiological sex steroid
      regimens which are inadequate at optimizing uterine characteristics.

      Human umbilical cord mesenchymal stem cells (hUCMSCs) and human cord blood mononuclear cells
      (hCBMNCs) have been shown to have the ability to modulate the immune response and enhance
      angiogenesis, suggesting the novel and promising therapeutic strategy for POF.

      In this study, the safety and efficacy of hUCMSCs and hCBMNCs transplantation combined with
      Hormone Replacement Therapy will be evaluated in patients with Premature Ovarian Failure.
      Participants will be followed for an expected average of 48 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Serum Level of follicle-stimulating hormone</measure>
    <time_frame>48 weeks after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uterine and Ovary characteristics of B ultrasound， including Uterine/Ovarian size and Blood Flow</measure>
    <time_frame>48 weeks after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Kupperman Score</measure>
    <time_frame>48 weeks after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events and Serious Adverse Events</measure>
    <time_frame>48 weeks after treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Premature Ovarian Failure，</condition>
  <arm_group>
    <arm_group_label>Group1 : HRT plus hUCMSCs treatment:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given HRT plus human cord mesenchymal stem cells transplantation with a 12 menstrual Cycle follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: HRT plus hCBMNCs and hUCMSCs therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given HRT plus combination of hCBMNCs together with hUCMSCs transplantation with a 12 menstrual Cycle follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group3 : HRT plus hCBMNCs treatment:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given HRT plus human cord blood mononuclear cells transplantation with a 12 menstrual Cycle follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4:Hormone Replacement Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given conventional therapy only with a 12 menstrual Cycle follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human umbilical cord mesenchymal stem cells</intervention_name>
    <arm_group_label>Group1 : HRT plus hUCMSCs treatment:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hUCMSCs and hCBMNCs</intervention_name>
    <arm_group_label>Group 2: HRT plus hCBMNCs and hUCMSCs therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human cord blood mononuclear cells</intervention_name>
    <arm_group_label>Group3 : HRT plus hCBMNCs treatment:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hormone Replacement Therapy</intervention_name>
    <arm_group_label>Group 4:Hormone Replacement Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between age 18- 39 years, Female only.

          -  Diagnosed with Premature Ovarian Failure，and currently receiving Hormone Replacement
             Therapy;

          -  Willing to sign the Informed Consent Form.

        Exclusion Criteria:

          -  Fragile X chromosome.

          -  polycystic ovary syndrome.

          -  HIV+.

          -  Autoimmune disease, e.g. lupus erythematosus, multiple sclerosis.

          -  Severe pulmonary and hematological disease, malignancy or hypo-immunity.

          -  Currently undertaking other treatment that may affect the safety/efficacy of stem
             cells.

          -  Pregnancy or lactation

          -  Enrollment in other trials in the last 3 months. • Other criteria the investigator
             consider improper for inclusion.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>FangMing Su, Master</last_name>
    <phone>86-755-25533018</phone>
    <email>sfmlxq@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fangming Su</last_name>
      <phone>86-755-25533018</phone>
      <email>sfmlxq@163.com</email>
    </contact>
    <investigator>
      <last_name>Fangming Su</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 2, 2012</lastchanged_date>
  <firstreceived_date>November 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hormone Replacement Therapy，</keyword>
  <keyword>Premature Ovarian Failure，</keyword>
  <keyword>Stem Cell Therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Menopause, Premature</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
